The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...
Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...
Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute.
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
Eli Lilly just gave investors several reasons to cheer.
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback